Plasma biomarkers of Alzheimer´s disease in the continuum of dementia with Lewy bodies
- Published on 02/07/2024
- Reading time: 4 min.
Patricia Diaz‐Galvan 1, Scott A. Przybelski 2, Alicia Algeciras‐Schimnich 1, Timothy G. Lesnick 2, Christopher G. Schwarz 1, Matthew L. Senjem 1, Jeffrey L. Gunter 1, Clifford R. Jack Jr. 1, Paul H Min 3, Manoj K. Jain 4, Toji Miyagawa 1, Leah K. Forsberg 1, Julie A. Fields 1, Rodolfo Savica 1, Jonathan Graff‐Radford 1, Vijay K Ramanan 1, David T. Jones 1, Hugo Botha 1, Erik K St Louis 1, David S. Knopman 1, Neill R Graff‐Radford 4, Tanis J Ferman 4, Ronald C. Petersen 1, Val J. Lowe 3, Brad F. Boeve 1, Kejal Kantarci 3
1
Mayo Clinic, Rochester, MN
USA
2
Mayo Clinic, Quantitative Health Sciences, Rochester, MN
USA
3
Mayo Clinic, Radiology, Rochester, MN
USA
4
Mayo Clinic, Jacksonville, FL
USA
Abstract
Background Patients with dementia with Lewy bodies (DLB) may have Alzheimer´s disease (AD) pathology. Plasma biomarkers of beta‐amyloid (Aß), phosphorylated tau (pTau), and neurodegeneration are sensitive to AD neuropathologic changes in AD dementia. While these plasma biomarkers are well tested in the AD continuum, their performance for concomitant AD pathology in the DLB continuum is still unclear.
Method We included patients with isolated...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Neurology
Receive our newsletter to stay up to date with the latest news in Neurology
